Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;27(6):472-478.
doi: 10.1097/MCO.0000000000001064. Epub 2024 Aug 5.

Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists

Noémie Beauregard  1 , Kurt McInnis  1 , Gary S Goldfield  2 , Éric Doucet  1
Affiliations
Review

Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists

Noémie Beauregard et al. Curr Opin Clin Nutr Metab Care. .

Abstract

Purpose of review: With obesity affecting over one billion people globally, understanding and managing this complex condition is more crucial than ever. This review explores the emerging role of GLP-1 receptor agonists (GLP-1RA) in weight management, focusing on their impact on energy balance. It highlights the necessity of this investigation due to the limited knowledge on both the short-term and long-term implications of GLP-1RA on energy expenditure (EE) and energy intake (EI).

Recent findings: GLP-1RA, such as liraglutide and semaglutide, have shown significant efficacy in promoting weight loss by reducing appetite, cravings and consequently, EI. Newer medications such as tirzepatide have demonstrated even greater weight loss success. Emerging evidence also suggests potential effects on EE, which could explain the greater weight loss success achieved with GLP-1 RA rather than typical lifestyle changes. However, comprehensive data on the total impact of these drugs on energy balance remain limited.

Summary: The findings underscore the promising role of GLP-1RA in obesity management, particularly through mechanisms influencing both EI and EE. Future research should focus on systematically measuring all components of energy balance to fully elucidate the mechanisms of GLP-1RA and optimize their therapeutic use for personalized medicine.

PubMed Disclaimer

References

    1. Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024; 403:1027–1050.
    1. Anderson JW, Luan J, Høie LH. Structured weight-loss programs: Meta-analysis of weight loss at 24 weeks and assessment of effects of intervention intensity. Adv Ther 2004; 21:61–75.
    1. Wadden TA. Treatment of obesity by moderate and severe caloric restriction: results of clinical research trials. Ann Intern Med 1993; 119 (Part 2):688–693.
    1. Wing RR, Jeffery RW. Effect of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance? Int J Obes Relat Metab Disord J Int Assoc Study Obes 1995; 19:67–73.
    1. Ryan D. Risks and benefits of weight loss: challenges to obesity research. Eur Heart J Suppl 2005; 7: (Suppl L): L27–L31.

MeSH terms